Sun Pharmaceutical Industries Ltd. (SUNPHARMA.NS), Friday announced data showing that Winlevi cream 1 percent reduces oil production and demonstrates stability in the presence of other commonly prescribed topical acne treatments.
The company explained that Winlevi is an androgen receptor inhibitor indicated for the topical treatment of acne vulgaris, in patients 12 years of age and older, that targets sebum production in the skin.
The study of Winlevi showed tolerability and acne severity improvement in patients with skin of color.
Currently, Sun Pharma's stock is trading at INR 1,860.40, up 0.62 percent on the National Stock Exchange.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.